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Abstract
Background: Timely identification of pathogens is crucial to minimize mortality in patients with
severe infections. Detection of bacterial and fungal pathogens in blood by nucleic acid amplification
promises to yield results faster than blood cultures (BC). We analyzed the clinical impact of a
commercially available multiplex PCR system in patients with suspected sepsis.
Methods: Blood samples from patients with presumed sepsis were cultured with the Bactec
9240™ system (Becton Dickinson, Heidelberg, Germany) and aliquots subjected to analysis with
the LightCycler® SeptiFast® (SF) Test (Roche Diagnostics, Mannheim, Germany) at a tertiary care
centre. For samples with PCR-detected pathogens, the actual impact on clinical management was
determined by chart review. Furthermore a comparison between the time to a positive blood
culture result and the SF result, based on a fictive assumption that it was done either on a once or
twice daily basis, was made.
Results: Of 101 blood samples from 77 patients, 63 (62%) yielded concordant negative results, 14
(13%) concordant positive and 9 (9%) were BC positive only. In 14 (13%) samples pathogens were
detected by SF only, resulting in adjustment of antibiotic therapy in 5 patients (7,7% of patients). In
3 samples a treatment adjustment would have been made earlier resulting in a total of 8
adjustments in all 101 samples (8%).
Conclusion: The addition of multiplex PCR to conventional blood cultures had a relevant impact
on clinical management for a subset of patients with presumed sepsis.
Background
Early adequate antibiotic treatment improves the out-
come of patients with sepsis [1-5]. Even if broad spectrum
antibiotics are used empirically, adjustments of antimi-
crobial therapy may be necessary. Generally adjustments
are based on the results of positive blood or other cultures
that are available after 8 to 48 hours [6].
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Additionally, the likelihood of a positive result in conven-
tional culture methods can be reduced by concomitant or
prior antibiotic treatment. Amplification of bacterial and
fungal nuclear acids directly from blood specimen is a
newly established detection method for pathogens. Tests
based on this method may improve clinical care by short-
ening the time to a positive result and by being more inde-
pendent of antibiotic pre-treatment. The impact of these
methods on therapeutic decisions and outcome has not
yet been studied.
We compared the results of a standard BC system with
those of a commercially available polymerase chain reac-
tion (PCR) based system in routine clinical management.
Primary goal of the study was to determine if results from
the additional PCR based system led to different therapeu-
tic decisions than the results from BC alone.
Secondary goal was to assess the concordance of both
methods and time saving effects with the use of a PCR-
based test.
Methods
A commercially available molecular based test system
(LightCycler®  SeptiFast®  (SF) Test; Roche Diagnostics,
Mannheim, Germany) was offered as an add-on diagnos-
tic tool free of charge supplemental to standard BCs taken
in patients with presumed sepsis at the Regensburg uni-
versity medical centre during an eight months period (July
2006 – March 2007). The test was made available to all
departments treating patients with sepsis by the microbi-
ology department. The decision to use the additional test
was solely made by the treating clinician.
The SeptiFast® Test is able to detect 25 different pathogens
directly from blood by real-time multiplex PCR (Table 1)
[7]. The limits of detection were 100 CFU/ml for coagu-
lase-negative staphylococci, C. glabrata and Streptococcus
spp. and 30 CFU/ml for all other pathogens listed in the
table [8].
Both the sample for the BC and the sample for the SF were
taken through the same blood drawing device. Both aero-
bic and anaerobic BC bottles (Bactec 9240 BC system, Bec-
ton Dickinson, Heidelberg, Germany) were inoculated
directly with 10 ml blood each and delivered to the micro-
biology department together with the aliquot for analysis
with the SF. Blood cultures were incubated for 7 days. The
SF-test was provided free of charge by the manufacturer.
A retrospective analysis of the test results and clinical data
was performed. Clinical data were extracted by chart
review (underlying illness, antibiotic pre-treatment, epi-
demiological data such as age, sex, length of stay, hospital
mortality, immunosuppression, SIRS criteria (Tempera-
ture ≤ 36°C or ≥ 38°C, heart rate ≥ 90 bpm, respiratory
rate ≥ 20 breaths/min or paCO2 < 32 mmHg, white blood
cell count ≥ 12,000 or ≤ 4,000 cells/mm3)) and by the
data provided for the test application. Immunosuppres-
sion was defined as being post organ-transplant, receiving
chemotherapy for malignant disease or receiving high
dose prednisolone (>20 mg/day). Those with chronic dis-
ease predisposing for infections such as chronic liver dis-
ease or alcoholism were not counted as such. Antibiotic
pre-treatment was defined as having received any antibi-
otic therapy within 24 hours before specimen collection.
Multiple samples per patient were allowed, if the times of
blood collection were at least 48 hours apart.
To determine the impact of the results on the patients'
therapy, data were independently reviewed by two infec-
tious disease specialists. They analyzed the current antibi-
otic therapy and possible adaptations necessary for
optimal treatment according to current standard of care.
In case of both SF and BC yielding positive results, the
possible time saving effect of the SF-test was determined.
Treatment adjustments were classified into two different
categories: 1) Treatment adjustment not necessary (either
due to coverage by the empirical therapy or to lacking
clinical relevance); 2) Treatment adjustment necessary
due to lacking coverage of empirical therapy.
Table 1: SeptiFast® Portfolio: Pathogens detected by SeptiFast®.
Gram-negative bacteria Gram-positive bacteria Fungal pathogens
Escherichia coli Staphylococcus aureus Candida albicans
Klebsiella pneumoniae Coagulase-negative Candida tropicalis
Klebsiella oxytoca Staphylococci Candida parapsilosis
Serratia marcescens Streptococcus pneumoniae Candida krusei
Enterobacter cloacae Streptococcus spp. Candida glabrata
Enterobacter aerogenes Enterococcus faecium Aspergillus fumigatus
Proteus mirabilis Enterococcus faecalis
Pseudomonas aeruginosa
Acinetobacter baumannii
Stenotrophomonas
maltophiliaBMC Infectious Diseases 2009, 9:126 http://www.biomedcentral.com/1471-2334/9/126
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In order to examine possible time saving effects of the
molecular based analysis, time to results of BCs was com-
pared to the time of SF results. At our institution BC
results are reported to the treating physician by telephone
call from 8 am to 7 pm Monday-Friday and 9 am – 4 pm
on weekends and holidays. A complete report including
antibiotic resistance testing results is faxed and sent by
mail. Due to the experimental status of the SF-test, the
results were not available on a daily basis. Therefore a vir-
tual once and twice daily analysis Monday-Friday was
assumed in order to achieve comparable time frames. For
the once daily simulation results were assumed to be
available by 2 pm if received by 8 am in concordance with
the turnaround times reported for the test. In the twice
daily setting results were assumed to be available by 2 pm
if SF samples were received by 8 am, if received by 1 pm
results were assumed to be available at 7 pm. We then
compared the time from drawing the blood samples to
the time a first positive BC result was reported and the vir-
tual SF result time.
Data collection and statistical analysis were performed
using Microsoft Office Access® (Version 2007, Microsoft
Corporation, Redmond, USA) and SPSS® (SPSS Inc, Ver-
sion 15, Germany).
Due to the retrospective and non-interventional design of
the analysis approval of the local ethics committee was
not required according to the guidelines of our hospital.
Results
Patient population
In the study period 101 samples of 77 patients were exam-
ined. The median age of the patients was 55 years (Table
2). In-Hospital mortality was 33% with a median length
of stay of 35 days. Eighty-three patients (82%) were
treated in the ICU while the blood samples were taken.
Two or more SIRS criteria were present in 79 patients at
the time of specimen collection (78%), one positive SIRS
criteria in 13 patients, no SIRS criteria in 8 patients (miss-
ing data in one patient). Thirty-five of the patients (45%)
were immunocompromised. In 40 patients from surgical
and 37 from medical wards a broad spectrum of diseases
and comorbidities was present. Concomitant antibiotic
therapy at the time of specimen collection had been
administered in 61 patients with 83 samples (81%) stud-
ied.
Isolated Pathogens
In 39 samples (38%) pathogens were identified from
either BC or SF (Table 3). Both methods yielded predom-
Table 2: Patient characteristics: Patient characteristics stratified by SeptiFast® (SF) results.
SF positive SF negative
SF and BC detected 
same pathogen
Only SF detected 
pathogen
SF and BC detected 
different pathogens
BC detected pathogen BC and SF neg.
Number of samples 14 12 3 9 63
Number of patients 12 8 2 7 48
Patients in ICU at 
time of specimen 
collection
11 11 2 9 50
Number of samples 
drawn with 
concomitant 
antimicrobial therapy
13 12 2 7 50
Median Age
(± SD) [years]
59 (± 18) 52 (± 17)
Gender 8 female/14 male 20 female/35 male
Median Duration of 
hospitalisation (± SD) 
[days]
40 (± 39) 34 (± 43)
Hospital mortality 36.4% 30.9%
Median Number of 
SIRS criteria (± SD)
2.9 (± 1.1) 2.2 (± 1.1)
BC = blood culture.BMC Infectious Diseases 2009, 9:126 http://www.biomedcentral.com/1471-2334/9/126
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inantly gram-positive bacteria. More pathogens were
found in the SF group of patients, mainly due to a higher
rate of fungal pathogens and a higher rate of Enterococcus
faecium, while the number of coagulase-negative Staphy-
lococci (CNS) was lower with SF. All differences were not
statistically significant (p > 0.05).
Concordance of BC and SF
Fourteen of 101 samples (13%) were concordant positive
in SF and BC systems. Sixty-three (62%) were negative in
both methods. Thus a concordant result was seen in 77%
of all samples. In 13 samples with a negative BC, patho-
gens were identified by SF (Table 4). In additional micro-
biological samples from the same patient, the identical
pathogen was isolated in 9 of those cases (bronchial lav-
age (3), wound swab (2), tracheal aspirate (1), urine (1),
ascites (1), gall fluid aspirate (1)); Table 5.
Fungal pathogens were detected more frequently with the
SF-test when present in other clinical isolates (3 Candida
species).  Enterococcus faecium infection was more often
diagnosed in the SF (n = 7) test compared to BC (n = 3),
although neither difference was statistically significant.
In 9 samples with positive BC the SF-test yielded negative
results (Table 6). Listeria monozytogenes isolated from a BC
was not detected by the SF-test due to the limited portfolio
of the SF-test. Another failure was attributed to technical
problems during the analysis. Three times CNS were iso-
lated by BC while SF did not give a positive result. Four
further samples with positive BC results had no positive
result in the SF analysis. Three of those were polymicro-
bial bloodstream infections with two samples with Entero-
coccus faecalis that failed detection and one Streptococcus
pneumoniae  bacteraemia. Retrospective analyses of the
original data of the LightCycler® system revealed the detec-
tion of Streptococcus pneumoniae that had been missed due
to a faulty software (V1.1.7., detected in review with
revised software, V1.2.1).
The median time to obtain the result of the SF analysis was
determined to be 18 hours, with a minimum of 6.75
hours and a maximum of 74 h (samples collected at the
beginning of the weekend) in the twice daily situation,
with a median time of 26,25 hours, a minimum of 6,75
hours and a maximum of 79 hours assuming a once daily
analysis.
Treatment adjustments
In samples with both BC and SF positive a change in ther-
apy would not have been necessary in 11 of the 14 cases
(Table 7). For one of those samples the BC results had
been available before completion of the actual SF analysis
and a change in therapy had already been executed.
Three samples of 3 different patients could be identified
where a treatment adjustment was deemed necessary. In
one case an antifungal drug was not included in the
empiric regimen; in two other cases vancomycin was nec-
essary additionally. The median time from specimen col-
lection to the SF result was 27 hours in the once daily and
18 hours in the twice daily setting in all BC and SF positive
Table 3: Isolated Pathogens: Pathogens identified in BC or SF; 7 
samples yielded polymicrobial results.
Species SeptiFast® Blood culture
Coagulase-negative staphylococci 3 6
Staphylococcus aureus 53
Enterococcus faecalis 23
Enterococcus faecium 73
Klebsiella pneumonia 21
Serratia marcescens 22
Escherichia coli 32
Enterobacter cloacae/aerogenes 21
Proteus mirabilis 11
Streptococcus species 1
Candida albicans 23
Candida glabrata 1
Aspergillus fumigatus 1
Candida tropicalis 11
Candida krusei 1
Streptococcus pneumoniae 1
Listeria monozytogenes 1
Total 34 28
Table 4: Overall results: Results of blood culture (BC) and 
SeptiFast® (SF)
BC positive BC negative Total SF
SF positive 14 13 27
SF negative 9* 63 73
Total BC 23 77 100#
* Two samples yielded two different pathogens by BC but just one by 
SF
# One sample yielding different species comparing SF with BC not 
included in table.
Table 5: Additional microbiological samples: Pathogens 
identified by culture from patients with positive SF and negative 
BC result.
Species Organ Site
Enterococcus faecium Wound swab
Enterococcus faecium Gall fluid aspirate
Enterococcus faecium Ascites
Enterococcus faecium Tracheal aspirate
Escherichia coli Urine culture
Streptococcus species Wound swab
Candida albicans Bronchial lavage, Skin swab groin
Candida krusei Bronchial lavage
Aspergillus fumigates Bronchial lavageBMC Infectious Diseases 2009, 9:126 http://www.biomedcentral.com/1471-2334/9/126
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samples. The SF median time in the 3 samples that
resulted in treatment adjustments was 21.5 hours for both
scenarios (once and twice daily: 7; 21.5; 22 hours) com-
pared to 29 hours median time for BC (29; 8; 43 hours)
for these individual cases.
Compared to the BC results of those samples this yields a
time saving of a median of 21 hours.
In samples with BC negative and SF positive results a treat-
ment adjustment was not deemed necessary in 8 of 13
samples (Table 7, Table 8). In three cases the additional
use of antifungal treatment was recommended. Two other
patients had not been treated for Enterococcus faecium and
vancomycin was recommended as an additional drug.
Taken together, based on our proposed virtual time frame
in which SF results would have become available, in 8 of
27 samples an adjustment of therapy would be triggered
by the SF results. Three of those would have been made
earlier while 5 would have been missed by conventional
BC. Thus the use of the SF-test had clinical consequences
in 8% (8 of 101) of all analysed samples.
As treatment recommendations were made post-hoc
based on the clinical data available at the time of the diag-
nostic results, we also looked at the actual clinical courses.
In all but one sample the treating clinicians had decided
in accordance with our post-hoc recommendations.
Discussion
In 39/101 samples from patients with suspected sepsis
pathogens were identified with either the use of BCs or a
PCR-based test for the identification of bacterial and fun-
gal pathogens in whole blood (SF-test).
Concordance for positive and negative results between BC
and SF (77%) was comparable to other studies [9,10].
With the BC results only, we identified positive results in
21% of all samples in comparison to 27.4% with the SF-
test. With SF more fungal pathogens and more Enterococ-
cus faecium were identified compared to BC. In contrast,
fewer CNS specimens were identified by SF compared to
conventional blood cultures.
One important question is if these pathogens additionally
detected by either SF or BC are clinically relevant or if
there are merely "innocent bystanders", i.e. the important
discrimination between contamination, colonisation or
true infection. In our patient cohort most pathogens
detected only by SF were also present in other specimens
Table 6: Negative SF and positive blood culture: Isolated Pathogens per Patient with negative SF and positive blood culture result
Pathogen Note
Candida albicans BC positive after 5 days
Streptococcus pneumonia Pathogen identified when looking retrospectively at Lightcycler® data
Enterococcus faecalis, Coagulase-negative staphylococci Unknown
Coagulase-negative staphylococci Suspected contamination
Coagulase-negative staphylococci Suspected contamination
Candida albicans Not enough blood for SF (750 μl instead of 3 ml)
Enterococcus faecalis, Coagulase-negative staphylococci Unknown
Listeria monocytogenes Not included in SF portfolio, Ampicillin added
E. cloacae E. cloacae found, E. faecium missed
Table 7: Positive blood culture and SeptiFast®: Isolated pathogens per patient with positive blood culture and positive SF result
Identified pathogen Therapeutical relevance
Escherichia coli No change: patient deceased before results became available, empirical therapy sufficient
Coagulase negative staphylococci Modification necessary: Vancomycin added
Serratia marcescens No change, empirical therapy sufficient
Staphylococcus aureus No change, BC results leading to change were available before SF
Serratia marcescens No change, empirical therapy started after sample collection sufficient
Enterococcus faecium Modification necessary: Vancomycin added
Klebsiella pneumoniae No change, empirical therapy sufficient
Candida tropicalis No change, empirical therapy started after sample collection sufficient
Staphylococcus aureus No change, empirical therapy sufficient
Proteus mirabilis No change, empirical therapy sufficient
Enterococcus faecalis No change, empirical therapy sufficient
Candida albicans Modification necessary: Fluconazole added
Staphylococcus aureus No change, empirical therapy sufficient
Escherichia coli No change: patient deceased before results became available, empirical therapy sufficientBMC Infectious Diseases 2009, 9:126 http://www.biomedcentral.com/1471-2334/9/126
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of the same patient suggesting a clinical relevance. These
results are in concordance with other studies where 12 of
14 respectively 31 of 42 pathogens additionally detected
by PCR were present in other samples of the same patient
[9,10].
CNS were rarely detected by the SF-test in our collective,
as the SF-test tries to omit positive results due to contam-
ination. This is in accordance with one other study, pre-
senting 102 patients without signs of infection with
19.6% positive BC and no CNS by SF [7]. In our study in
all patients with CNS identified by BC the antibiotic treat-
ment was not adjusted, alluding to the considered insig-
nificance by the treating clinicians. Whether at least one of
them was clinically relevant could not be judged retro-
spectively.
Our study showed that the use of SF in addition to BC led
to the identification of more pathogens. If this was influ-
enced by concomitant antibiotic therapy could not be
addressed in our study, as 82% of the patients were
already on treatment at specimen collection.
Our assumed twice daily analysis for the SF-test would
have led to a median time to final results of 18 hours.
Compared to usual turnaround times for BC results, this
yields a clear time advantage for the SF-test. Immediate
processing of specimens could further shorten the time to
final results to 6.5 h [10]. If this approach is feasible in a
routine hospital setting has yet to be examined.
Additional pathogens were identified in 5 cases and in 3
samples the rapid SF-test would have led to earlier adjust-
ment of antibiotic therapy. In total the use of the test
would have resulted in therapeutic consequences in 8
(8%) patients.
On the other side, 9 pathogens were not detected by SF.
One of them is not included in the PCR portfolio, thus no
conclusions can be drawn regarding sensitivity. Alarming
is the failure of detection of S. pneumoniae, even if this
could be attributed to a software problem that was solved
in newer software versions. With regard to the missed pol-
ymicrobial infections it is unclear why these were not
detected by SF. A possible explanation might be the com-
petitive growth in vivo that does not allow both patho-
gens to reach a level resulting in a positive SF test.
All detection failures and the necessity of antibiotic resist-
ance testing underline the importance of using the SF test
additionally to standard BC.
If therapeutic adjustments initiated by the SF-test have an
impact on the survival of patients with sepsis could not be
determined in this study. Studies indicate that patients do
not have a benefit from changes in antibiotic therapy if
the initial empiric therapy did not cover the causative
pathogen [4]. As those studies are based on the results
obtained with current culture systems an average delay of
1–2 days has to be assumed [6]. The effect of shortening
this time interval with the use of a PCR test has yet to be
examined [11].
Invasive fungal infections have an especially high mortal-
ity [4,12,13]. Studies have demonstrated that adverse
patient outcomes are related to late or inadequate antibi-
otic treatment. As the SF-test was superior in detecting
fungal pathogens and delivers results more rapidly, the
use of SF may improve patient outcomes.
The cost benefit of the SF may differ in different clinical
situations or patient populations. Special equipment and
specially trained personnel are necessary to perform the
Table 8: Positive SeptiFast® and negative blood culture: Isolated Pathogens per Patient with positive SF and negative blood culture 
result
Pathogen Therapeutical relevance
Coagulase negative Staphylococci No change, empirical therapy sufficient and probable contamination
Enterococcus faecium No change, empirical therapy sufficient
Enterococcus faecium Modification necessary: Vancomycin added
Enterococcus faecium No change, empirical therapy sufficient
Enterococcus faecium, Klebsiella pneumoniae, Enterobacter cloacae/aerogenes No change, empirical therapy sufficient
Escherichia coli No change: patient deceased before results became available, empirical 
therapy sufficient
Candida krusei No change, empirical therapy sufficient
Streptococcus species No change, empirical therapy sufficient
Enterococcus faecium Modification necessary: Vancomycin added
Staphylococcus aureus No change, empirical therapy sufficient
Enterococcus faecium, Candida glabrata Modification necessary: Voriconazole added
Aspergillus fumigatus Modification necessary: Voriconazole added. Growth of colonies from 
broncho-alveolar-lavage Aspergillus-Ag elevated.
Candida albicans Modification necessary: Caspofungin addedBMC Infectious Diseases 2009, 9:126 http://www.biomedcentral.com/1471-2334/9/126
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test. The cost of individual tests will be influenced by the
intended turnaround time as well as by the availability
outside normal working hours. Cost and cost-effective-
ness analyses will have to be done for different scenarios.
Our study had several limitations. Only 80% of the
patients presented with two or more SIRS criteria at the
time of the specimen collections. But as the rate of immu-
nosuppressed patients was high, a high index of suspicion
was present in the remaining 20%. Additionally, it was a
non-randomized study, where the decision to use the
additional test was solely taken by the treating clinician.
Thus a selection bias has to be assumed that may influ-
ence the rate and types of pathogens found in our sam-
ples. Further, it is a single centre study with a small study
size, thus possibly limiting the generalisability of the
results. Nevertheless the design of our study may mirror
clinical reality more exact than randomized controlled tri-
als. The patients' characteristics in our study are well com-
parable to those of patients from sepsis studies or cohorts,
including one at our institution [14].
Conclusion
Our study shows that the use of a rapid molecular diag-
nostic test for the identification of bacterial and fungal
pathogens may lead to a higher rate of early adequate anti-
biotic therapy in approximately 8% of patients with sus-
pected sepsis. Due to the small sample size and the design
of our study cost effectiveness analyses were not feasible.
They are warranted in further studies.
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